ZTS
Zoetis Inc. · Healthcare
118.26
0.27%(+0.32)
Prev. Close118.50
0.20%(+0.24)
Pre-marketLast Updated: — ET
52W L: $113.2952W H: $172.23
$118.46
CHG-2.90 (-2.39%)
H$122.96
L$113.11
VOL52M
ZTS (1h)
Zoetis Inc. · Healthcare
Ascent Group LLC reduced its stake in Zoetis Inc. (NYSE: ZTS) by 31.1% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 12,563 shares of the company's stock after selling 5,676 shares during the quarter. Ascent Group LLC's holdings in Zoetis were worth
Nvwm LLC trimmed its holdings in Zoetis Inc. (NYSE: ZTS) by 85.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,063 shares of the company's stock after selling 11,712 shares during the quarter. Nvwm LLC's holdings in Zoetis were worth $260,000 at
McBroom and Associates LLC lowered its position in shares of Zoetis Inc. (NYSE: ZTS) by 72.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,849 shares of the company's stock after selling 21,006 shares during the quarter. McBroom and Associates LLC's
Zoetis offers broad diversification across hundreds of animal health products, with nearly equal U.S. and international revenue exposure. ZTS posted resilient Q4 2025 results, with 3% revenue growth, 5.7% EPS growth, and a robust 27%+ non-GAAP net margin, outperforming consensus. Key 2026 catalysts include launches of next-generation osteoarthritis drugs Portela and Lenivia, targeting improved compliance and expanded market reach.
Aberdeen Group plc boosted its stake in shares of Zoetis Inc. (NYSE: ZTS) by 7.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,188,371 shares of the company's stock after purchasing an additional 79,220 shares during the period. Aberdeen
Zoetis Inc. (ZTS) is rated a hold, as shares trade near fair value with limited upside despite sector leadership and defensive qualities. The company guides for 3-5% organic operational growth in 2026 and remains very shareholder-friendly, reflected in a 20% 5-year DPS growth and 6.6% buyback yield. Zoetis faces risks from pipeline concentration, potential margin pressure due to increasing competition and product setbacks, notably Librela's 32% sales decline due to safety concerns.
Sarbaugh Keith
officer: Executive Vice President
1,528 SH @ $0.00
2026-03-31
Sarbaugh Keith
officer: Executive Vice President
524 SH @ $118.21
2026-03-31
Sarbaugh Keith
officer: Executive Vice President
1,528.017 SH @ $0.00
2026-03-31
FULLER JULIE
officer: Executive Vice President
669.337 SH @ $0.00
2026-03-27
Joseph Wetteny
officer: Chief Financial Officer
2,114.756 SH @ $0.00
2026-03-27
PECK KRISTIN C
director, officer: Chief Executive Officer
4,391.261 SH @ $0.00
2026-03-27
Driscoll Rimma
officer: Executive Vice President
641.744 SH @ $0.00
2026-03-27
Esch Kevin
officer: Executive Vice President
219.953 SH @ $0.00
2026-03-27